



EU Transparency – Hurdles Still to Come

CLE Conference 08/03/2023

Unrestricted

Transparency is Critical

- **Wider society: building trust & accountability**
 - **Review of regulator decisions: important for regulatory evolution and challenge by stakeholders**
 - **Equality of treatment between applicants and equivalent scenarios**
 - **Supports decision making by industry, understanding precedents**
 - **Good policy making: choices for the future can only be made where the relevant facts are known**
-



Transparency Mechanisms

Proactive Disclosure

- Sector specific legislation:
 - Transparency Regulation – 2019/1381
 - Notification of studies
 - Proactive publication
 - Confidentiality requests
- Some implementation "outsourced" to soft law measures – EFSA's "*Practical Arrangements*"
- Company voluntary initiatives

Reactive Disclosure

- Horizontal legislation:
 - Access Regulation 1049/2001
 - Aarhus Regulation 1367/2006
- National transparency legislation
- Typical threshold requirements:
 - Specific request required, limited volume
- Aarhus Convention also relevant for some requests in under national legislation

Common to both regimes – the need to consider the relevance and availability of exceptions (e.g. confidential business information) and relationship to other rights (e.g. GDPR)

Transparency Mechanisms – Factors to Consider


- **Interrelationships between proactive & reactive regimes:**
 - Partially a response to the anticipated numbers of reactive requests?
 - Potential for differential application of relevant tests and different results, in particular the scope of exemptions – despite some cross reference
 - Also compare to the operations of other regimes, e.g. EMA. Fragmentation?
- **Difficulties with proactive disclosure – simple in theory but resource intensive in practice:**
 - EFSA Practical Arrangements and operational difficulties with implementation and claims for confidentiality & protection of personal data
 - Importance of flexibility. Solvable... but with significant effort?
 - Practical Arrangements cannot overwrite other substantive requirements. Delegation principles involved, and Arrangements expressly required to be “*in accordance with this Regulation and other relevant Union law*”

Core Concepts for Implementation – Scope of CBI Exemption

● Reactive Scope – Aarhus

Hautala – available unless the **purpose** of the information is to assess emissions into the environment

Why was the information submitted? What use did the regulator make of it?



● Proactive Scope - GFL

Available for limited subset of information; but not if that information is “*relevant to the assessment of safety*”

Core Concepts for Implementation – Scope of CBI Exemption

- Who decides the “purpose” of the information or if it is “relevant to the assessment of safety” and more importantly, how?
 - Who: Significant caseload and need to consider arguments by information owner. Resource constraints...
 - How: Need to ensure decisions are harmonised and taken on a principled and reproducible basis, and in accordance with the relevant law. Avoid conflict between reactive/proactive tests, but within the law.
- Examples – inert coformulants – water? Other formulation details not considered as part of the safety assessment?
- Potential for further conflict, e.g. GDPR requirements
- Further litigation eventually necessary to seek clarity?

Core Concepts for Implementation – Equal Treatment

- Need to apply principles consistently – neutral to applicant and content
 - e.g. “me too” product dossiers
 - No legal basis for differential application of reactive publication and the *Hautala* test; the safety assessment of all products is within scope
 - All products are assessed on their own merits
- Choices regarding scope and process should be workable for all scenarios
- Temptation to argue that situations are somehow different, possibly to reduce significant workload due to application of principles

Further Implications to Consider

- **Data protection** – simply because a study is now transparent, no automatic right to use that study “*for the benefit*” of another applicant.
 - Regardless of whether obtained under transparency or other means (e.g. Regulation 2020/1740)
 - e.g. relevant product authorisations are automatically extended when a new AI submission passes a renewal completeness check. The information in that renewal dossier has indeed then been used “*for the benefit*” of the other applicant, including in relation to extending its product authorisations. If the data is still protected, this should be considered an infringement.
- **Transparency during the decision making process itself** – NGO litigation to use reactive transparency requests to reveal MS positions of during approval procedures
 - Will also be relevant in other situations – e.g. expert meetings

Questions & Discussion